Forte Biosciences, INC

Global immunology company argenx will acquire Forte Biosciences for $77 per share in cash, adding Forte's lead drug candidate FB102 to its pipeline.

Forte Biosciences announced positive top-line results from its Phase 1b study of FB102 in vitiligo, showing statistically significant improvements in facial skin depigmentation.

Forte Biosciences held its 2026 annual meeting, where stockholders approved an amended equity incentive plan and ratified the appointment of KPMG LLP.

Forte Biosciences announced its first quarter 2026 financial results, reporting increased R&D expenses and a net loss, while also highlighting the FDA's Fast Track Designation for its FB102 therapeutic candidate in celiac disease.

Forte Biosciences announced the pricing of a $150 million public offering of common stock, with net proceeds expected to fund clinical development and general corporate purposes.

Forte Biosciences announced its full year 2025 financial results and provided updates on the clinical development of its lead therapeutic candidate, FB102, for autoimmune diseases.

Forte Biosciences reported a net loss of $22.1 million for Q1 2026, with research and development expenses significantly increasing, while cash reserves remain substantial following a recent public offering.

Forte Biosciences reports significant progress in its FB102 clinical programs for autoimmune diseases, backed by a strengthened cash position following recent capital raises, despite continued operating losses.

Forte Biosciences announced positive Phase 1b celiac disease trial results for FB102 and significantly strengthened its cash position through recent public offerings.

Forte Biosciences reports a net loss for Q1 2025, while progressing clinical trials for FB102 in celiac disease and non-segmental vitiligo.

Forte Biosciences reports a net loss of $28.3 million for the first nine months of 2024 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Forte Biosciences reports a net loss of $19.9 million for the first six months of 2024, while advancing its lead drug candidate, FB102, into patient studies.

Forte Biosciences announced positive Phase 1b celiac disease trial data and successfully raised $75 million in a public offering, while continuing to incur significant net losses.

Forte Biosciences details its financial results for 2024 and provides an update on the clinical development of its lead product candidate, FB102.

Forte Biosciences has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

Forte Biosciences' 10-K filing details the company's financial status, ongoing FB-102 clinical trial, and regulatory landscape.

Forte Biosciences CFO Antony A. Riley reports transactions involving common stock and restricted stock units, including acquisitions and disposals.

Paul A. Wagner, Director and Officer of Forte Biosciences, Inc., acquired 1,250 Restricted Stock Units (RSUs) on July 1, 2026, as detailed in a Form 4 filing.

Forte Biosciences CFO Antony A. Riley acquired 22,000 stock options with an exercise price of $17.15, vesting over four years starting June 16, 2026.

Forte Biosciences, Inc. reports the grant of stock options to Director and Officer Paul A. Wagner, with vesting over four years.

Forte Biosciences, Inc. director Stephen K. Doberstein was granted 18,353 restricted stock units (RSUs) on May 29, 2026, vesting on the first annual stockholder meeting after that date.

Forte Biosciences, Inc. director Shivpreet Singh Kapoor was granted 18,353 restricted stock units, vesting on the first annual stockholder meeting after May 29, 2026.

Forte Biosciences announces its 2025 Annual Meeting of Stockholders to be held virtually on May 29, 2025, featuring proposals for director elections and ratification of the company's independent auditor.

Forte Biosciences is asking stockholders to approve an amended and restated 2021 Equity Incentive Plan to attract and retain talent.

Forte Biosciences is asking stockholders to approve a reverse stock split and an amended equity incentive plan at its upcoming annual meeting.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 3.2% of Forte Biosciences, Inc. common stock as of June 30, 2026.

Federated Hermes, Inc. and related entities have filed a Schedule 13G, reporting beneficial ownership of 10.31% of Forte Biosciences, Inc. common stock as of June 30, 2026.

Millennium Management LLC and Israel A. Englander have reported a 5.2% beneficial ownership stake in Forte Biosciences, Inc. via a Schedule 13G filing.

OrbiMed Advisors LLC and OrbiMed Capital LLC have filed an amendment to their Schedule 13G, reporting a combined 5.8% beneficial ownership in Forte Biosciences, Inc.

Alger Associates, Inc. has filed an amended Schedule 13G reporting a 10.2% beneficial ownership stake in Forte Biosciences, Inc.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 9.99% of Forte Biosciences, Inc. common stock.